CLINICAL_TRIALS
trial_result
· 2022-03-29
Clinical Trial Update: MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease [Phase 2]
Summary
Phase 2 clinical trial update for MW150, a stress kinase inhibitor, in patients with Alzheimer's disease.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Neurokine Therapeutics | Conditions: Alzheimer Disease | Phase 2 | Status: UNKNOWN